Barinthus Biotherapeutics (BRNS) Treasury Shares (2020 - 2026)

Barinthus Biotherapeutics' (BRNS) quarterly Treasury Shares came in at $792724.0 in Q1 2026, down 8.33% on a QoQ basis from $864724.0 in Q4 2025.

Barinthus Biotherapeutics (BRNS) Treasury Shares (2020 - 2026) Analysis & Trends

Barinthus Biotherapeutics (BRNS) has 4 years of Treasury Shares data on file, last reported at $792724.0 in Q1 2026.

Quarterly Treasury Shares changed N/A year-over-year to $792724.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $792724.0 (changed N/A YoY) and the FY2025 annual result came in at $864724.0, changed N/A from the prior year.
Treasury Shares eased to $792724.0 in Q1 2026, from $864724.0 in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $864724.0 in Q4 2025 to a low of $792724.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Barinthus Biotherapeutics	25.40 Mn	25.40 Mn	-	-

Download Data